Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on March 11, 2016, primarily detailing amendments to its Severance Plan. These amendments were made in conjunction with the previously announced leadership transition where John C. Martin, Ph.D. moved to Executive Chairman and John F. Milligan, Ph.D. assumed the role of President and Chief Executive Officer, effective March 10, 2016. The amendments ensure that both Dr. Martin and Dr. Milligan will receive severance benefits consistent with what Dr. Martin previously received as CEO, generally equivalent to two to three times their base salary plus annual bonus. Notably, the revised plan eliminates the "golden parachute" excise tax gross-up that would have been available to certain executives, including Drs. Martin and Milligan. This change reflects a shift in executive compensation policy, removing a feature designed to offset potential excise taxes on large severance payments. The filing also includes technical and clarifying revisions to the plan document.
Key Highlights
- 1Leadership Transition: John F. Milligan, Ph.D. appointed President and CEO, while John C. Martin, Ph.D. transitions to Executive Chairman, effective March 10, 2016.
- 2Severance Plan Amendments: Compensation Committee approved changes to the Severance Plan to align benefits for the new CEO and Executive Chairman.
- 3Consistent Severance Benefits: Both Dr. Martin and Dr. Milligan will receive severance benefits similar to those previously provided to Dr. Martin as CEO (2-3x base salary + bonus).
- 4Elimination of 'Golden Parachute' Tax Gross-up: The amended plan removes the excise tax gross-up provision for certain executives, including the new leadership.
- 5Technical Clarifications: The filing notes other technical and clarifying revisions to the Severance Plan document.
- 6Exhibit Filed: The amended and restated Gilead Sciences, Inc. Severance Plan (dated March 8, 2016) is filed as an exhibit (Exhibit 10.1).